Cell Therapy Delivery System Licensing: CAR-T Infusion and Cryogenic Logistics Patents

TL;DR
Cell therapy delivery licensing covers CAR-T infusion bag manifold patents, cryogenic shipper dewar designs, and closed-system vein-to-vein logistics platforms. CDMOs and hospital networks negotiate field-of-use licenses separate from cell construct IP. See our cell therapy delivery system licensing guide and gene therapy platform licensing article by the PatentPaper research team.

CAR-T Infusion and Closed-System Manifold Patents

Licensing negotiations cover infusion bag spike connector geometries, closed-system manifold valve sequences preventing microbial ingress, and bedside thaw-and-infuse workflow controller patents.

Example: A 2024 CDMO licensing deal granted non-exclusive rights to a cryobag manifold patent family covering dual-spike connector sequences used in autologous CAR-T bedside preparation across twelve U.S. transplant centers.

Cryogenic Vein-to-Vein Logistics Platforms

Shipper dewar vacuum panel patents, temperature logger telemetry protocols, and chain-of-custody RFID tag antenna designs form separate licensing stacks from cell construct and vector IP.

Hospital Network and Site-of-Care Licensing

Hospital networks negotiate site licenses for delivery platforms while cell therapy developers retain construct patents, requiring clear field-of-use boundaries in master service agreements.

CDMO Capacity and Platform Exclusivity

CDMOs structure platform exclusivity tiers reserving manifold and logistics patents for anchor clients while granting non-exclusive cryogenic shipper licenses to regional distributors.

Regulatory and Pharmacovigilance Coordination

FDA BLA supplements reference licensed delivery components; licensors maintain change control obligations over manifold materials affecting leachables and infusion compatibility testing.

FAQ

What is cell therapy delivery licensing?

Patent licensing for infusion systems, cryogenic logistics, and bedside preparation platforms separate from cell construct IP.

Why separate delivery from construct patents?

CDMOs and hospitals use common delivery platforms across multiple cell therapy products requiring distinct license fields.

Are cryogenic shipper patents licensable independently?

Yes. Dewar and telemetry patents often form standalone licensing stacks from cell line and vector portfolios.

How do site-of-care licenses work?

Hospital networks obtain non-exclusive delivery platform rights while developers license construct patents per product.

Do BLA filings reference delivery licenses?

Yes. Licensed manifold and shipper components appear in CMC sections with licensor change control obligations.

Can exclusivity block competing CDMO capacity?

Platform exclusivity clauses may reserve manifold patents for anchor clients; negotiate carve-outs for second-source CDMOs.

Which PatentPaper articles complement cell therapy delivery licensing?

Our cell therapy delivery system licensing guide and gene therapy platform licensing article by the PatentPaper research team address platform licensing structures.

Review layer 1: Practical review notes for Cell Therapy Delivery System Licensing: CAR-T Infusion and Cryogenic Logistics Patents

Review layer 1: For cell therapy delivery licensing, separate the legal basis, patent-office step, and commercial evidence needed in a dispute. Sources such as fda.gov, isctglobal.org, usp.org help confirm fees, deadlines, term, and forum from primary material rather than secondary summaries.

Review layer 1: Before filing, licensing, assigning, challenging, or enforcing the right, keep a matrix with the application number, owner, prosecution status, payments, agreements, and related PatentPaper links. That record makes later decisions easier to defend.

Review layer 1: Check legal status before sending a notice.
Review layer 1: Save official receipts and office correspondence.
Review layer 1: Compare the main claim with the product actually sold.

Review layer 2: Practical review notes for Cell Therapy Delivery System Licensing: CAR-T Infusion and Cryogenic Logistics Patents

Review layer 2: For cell therapy delivery licensing, separate the legal basis, patent-office step, and commercial evidence needed in a dispute. Sources such as fda.gov, isctglobal.org, usp.org help confirm fees, deadlines, term, and forum from primary material rather than secondary summaries.

Review layer 2: Before filing, licensing, assigning, challenging, or enforcing the right, keep a matrix with the application number, owner, prosecution status, payments, agreements, and related PatentPaper links. That record makes later decisions easier to defend.

Review layer 2: Check legal status before sending a notice.
Review layer 2: Save official receipts and office correspondence.
Review layer 2: Compare the main claim with the product actually sold.

Review layer 3: Practical review notes for Cell Therapy Delivery System Licensing: CAR-T Infusion and Cryogenic Logistics Patents

Review layer 3: For cell therapy delivery licensing, separate the legal basis, patent-office step, and commercial evidence needed in a dispute. Sources such as fda.gov, isctglobal.org, usp.org help confirm fees, deadlines, term, and forum from primary material rather than secondary summaries.

Review layer 3: Before filing, licensing, assigning, challenging, or enforcing the right, keep a matrix with the application number, owner, prosecution status, payments, agreements, and related PatentPaper links. That record makes later decisions easier to defend.

Review layer 3: Check legal status before sending a notice.
Review layer 3: Save official receipts and office correspondence.
Review layer 3: Compare the main claim with the product actually sold.